124 related articles for article (PubMed ID: 7519674)
21. Once versus twice daily administration of didanosine in children with symptomatic HIV-associated disease who were intolerant to or clinically deteriorated on zidovudine. The Italian Pediatric Collaborative Study Group on Didanosine.
Marchisio P; Principi N; Gabiano C; Galli L; Gattinara GC; Caselli D; Zuccotti G; La Regina A; Paga C
Antivir Ther; 1997 Jan; 2(1):47-55. PubMed ID: 11322266
[TBL] [Abstract][Full Text] [Related]
22. Rates and risk factors for adverse events associated with didanosine in the expanded access program.
Schindzielorz A; Pike I; Daniels M; Pacelli L; Smaldone L
Clin Infect Dis; 1994 Dec; 19(6):1076-83. PubMed ID: 7888537
[TBL] [Abstract][Full Text] [Related]
23. Zidovudine compared with didanosine in patients with advanced HIV type 1 infection and little or no previous experience with zidovudine. AIDS Clinical Trials Group.
Dolin R; Amato DA; Fischl MA; Pettinelli C; Beltangady M; Liou SH; Brown MJ; Cross AP; Hirsch MS; Hardy WD
Arch Intern Med; 1995 May; 155(9):961-74. PubMed ID: 7726705
[TBL] [Abstract][Full Text] [Related]
24. Development of resistance of zidovudine (ZDV) and didanosine (ddI) in HIV from patients in ZDV, ddI and alternating ZDV/ddI therapy.
Nielsen C; Bruun L; Mathiesen LR; Pedersen C; Gerstoft J
AIDS; 1996 Jun; 10(6):625-33. PubMed ID: 8780817
[TBL] [Abstract][Full Text] [Related]
25. The impact of zidovudine compared with didanosine on health status and functioning in persons with advanced HIV infection and a varying duration of prior zidovudine therapy. AIDS Clinical Trials Group 116/117 Study Group.
Bozzette SA; Kanouse DE; Duan N; Berry S; Richman DD
Antivir Ther; 1996 Jan; 1(1):21-32. PubMed ID: 11322256
[TBL] [Abstract][Full Text] [Related]
26. Long-term effectiveness and safety of didanosine combined with lamivudine and efavirenz or nevirapine in antiretroviral-naive patients: a 9-year cohort study in Senegal.
Laurent C; Tchatchueng Mbougua JB; Ngom Guèye NF; Etard JF; Diouf A; Landman R; Molinari N; Girard PM; Sow PS; Ndoye I; Delaporte E;
Trop Med Int Health; 2011 Feb; 16(2):217-22. PubMed ID: 21087377
[TBL] [Abstract][Full Text] [Related]
27. Relation of peripheral neuropathy to HIV treatment in four randomized clinical trials including didanosine.
Kelleher T; Cross A; Dunkle L
Clin Ther; 1999 Jul; 21(7):1182-92. PubMed ID: 10463516
[TBL] [Abstract][Full Text] [Related]
28. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II).
Eron JJ; Murphy RL; Peterson D; Pottage J; Parenti DM; Jemsek J; Swindells S; Sepulveda G; Bellos N; Rashbaum BC; Esinhart J; Schoellkopf N; Grosso R; Stevens M
AIDS; 2000 Jul; 14(11):1601-10. PubMed ID: 10983647
[TBL] [Abstract][Full Text] [Related]
29. A randomized trial (ISS 901) of switching to didanosine versus continued zidovudine after the diagnosis of AIDS.
Vella S; Floridia M; Dally LG; Tomino C; Fragola V; Weimer LE; Milazzo F; Mazzotta F; Moroni M; Pastore G; Scalise G; Sinicco A; Ortona L; De Rienzo B; Dianzani F
J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Aug; 12(5):462-9. PubMed ID: 8757422
[TBL] [Abstract][Full Text] [Related]
30. Meta-analysis of five randomized controlled trials comparing continuation of zidovudine versus switching to didanosine in HIV-infected individuals.
Raboud JM; Montaner JS; Rae S; Kahn J; Hammer SM; Katzenstein DA; Pavia A; Dolin R; Hughes MD; Cross A; Beltangady M; Gatell J; Dunkle L; Smaldone L
Antivir Ther; 1997 Dec; 2(4):237-47. PubMed ID: 11327443
[TBL] [Abstract][Full Text] [Related]
31. Effect of antiretroviral combination therapy (zidovudine/didanosine or zidovudine/lamivudine) on quantitative plasma human immunodeficiency virus-ribonucleic acid in children and adolescents infected with human immunodeficiency virus.
Sölder B; Wintergerst U; Notheis G; Eberle J; Gürtler L; Belohradsky BH
J Pediatr; 1997 Feb; 130(2):293-9. PubMed ID: 9042135
[TBL] [Abstract][Full Text] [Related]
32. Use of didanosine in zidovudine-intolerant patients infected with human immunodeficiency virus.
Nelson MR; Moyle GJ; Gazzard BG
Clin Infect Dis; 1993 Feb; 16 Suppl 1():S59-62. PubMed ID: 8093848
[TBL] [Abstract][Full Text] [Related]
33. A randomized pilot study of alternating or simultaneous zidovudine and didanosine therapy in patients with symptomatic human immunodeficiency virus infection.
Yarchoan R; Lietzau JA; Nguyen BY; Brawley OW; Pluda JM; Saville MW; Wyvill KM; Steinberg SM; Agbaria R; Mitsuya H
J Infect Dis; 1994 Jan; 169(1):9-17. PubMed ID: 7903976
[TBL] [Abstract][Full Text] [Related]
34. A comparison of zidovudine, didanosine, zalcitabine and no antiretroviral therapy in patients with advanced HIV disease.
Torres RA; Barr MR; McIntyre KI; Thornton JR; Shay WM; Feldman RD; George NJ; Britton DJ
Int J STD AIDS; 1995; 6(1):19-26. PubMed ID: 7727578
[TBL] [Abstract][Full Text] [Related]
35. [Pancreatic disease in patients with HIV treated with didanosine (DDI)].
Ortega González E; Martín Herrera A; López de Medrano V; de Lelis FP; Ronda Gasulla FA; Gil Egea M; Ballester Belda E; Herrera Ballester A
Rev Esp Enferm Dig; 1996 Feb; 88(2):114-7. PubMed ID: 8664067
[TBL] [Abstract][Full Text] [Related]
36. Five-year follow-up of a phase I study of didanosine in patients with advanced human immunodeficiency virus infection.
Nguyen BY; Yarchoan R; Wyvill KM; Venzon DJ; Pluda JM; Mitsuya H; Broder S
J Infect Dis; 1995 May; 171(5):1180-9. PubMed ID: 7751692
[TBL] [Abstract][Full Text] [Related]
37. Effect of lamivudine in HIV-infected persons with prior exposure to zidovudine/didanosine or zidovudine/zalcitabine.
Albrecht MA; Hughes MD; Liou SH; Katzenstein DA; Murphy R; Balfour HH; Para MF; Valdez H; Hammer SM;
AIDS Res Hum Retroviruses; 2000 Sep; 16(14):1337-44. PubMed ID: 11018853
[TBL] [Abstract][Full Text] [Related]
38. Neurologic, neurocognitive, and brain growth outcomes in human immunodeficiency virus-infected children receiving different nucleoside antiretroviral regimens. Pediatric AIDS Clinical Trials Group 152 Study Team.
Raskino C; Pearson DA; Baker CJ; Lifschitz MH; O'Donnell K; Mintz M; Nozyce M; Brouwers P; McKinney RE; Jimenez E; Englund JA
Pediatrics; 1999 Sep; 104(3):e32. PubMed ID: 10469815
[TBL] [Abstract][Full Text] [Related]
39. Alternating treatment with didanosine and zidovudine versus either drug alone for the treatment of advanced HIV infection. The Alter Study. Nordic HIV Therapy Group.
Gerstoft J; Melander H; Bruun JN; Pedersen C; Głtzsche PC; Berglund O; Mathiesen L; Skinhłj P; Norrby SR
Scand J Infect Dis; 1997; 29(2):121-8. PubMed ID: 9181646
[TBL] [Abstract][Full Text] [Related]
40. Incidence of pancreatitis in HIV-infected patients receiving nucleoside reverse transcriptase inhibitor drugs.
Moore RD; Keruly JC; Chaisson RE
AIDS; 2001 Mar; 15(5):617-20. PubMed ID: 11316999
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
